Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

The Managed Healthcare Executive 2025 State of the Industry survey is a timely snapshot of how payers, providers and pharmacy ...

Teledermatology's growth in 2025 improved efficiency and accessibility, with virtual visits reducing costs and saving time for patients and doctors. Hybrid models combining live video and photo ...

A study of more than 1 million UK medical records found that getting a flu vaccine between ages 40 and 50 did not increase Parkinson’s disease risk and was even associated with a lower estimated ...